• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

RA190 假定的 Rpn13 抑制剂的物理和功能分析。

Physical and Functional Analysis of the Putative Rpn13 Inhibitor RA190.

机构信息

Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458, USA.

Department of Molecular Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.

出版信息

Cell Chem Biol. 2020 Nov 19;27(11):1371-1382.e6. doi: 10.1016/j.chembiol.2020.08.007. Epub 2020 Aug 27.

DOI:10.1016/j.chembiol.2020.08.007
PMID:32857985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7680414/
Abstract

Rpn13 is one of several ubiquitin receptors in the 26S proteasome. Cys88 of Rpn13 has been proposed to be the principal target of RA190, an electrophilic small molecule with interesting anti-cancer activities. Here, we examine the claim that RA190 mediates its cytotoxic effects through engagement with Rpn13. We find no evidence that this is the case. In vitro, RA190 is has no measurable effect on any of the known interactions of Rpn13. In cellulo, we see no physical engagement of Rpn13 by RA190, either on C88 or any other residue. However, chemical proteomics experiments in two different cell lines reveal that dozens of other proteins are heavily engaged by RA190. Finally, increasing or reducing the level of Rpn13 in HeLa and melanoma cells had no effect on the sensitivity of HeLa or melanoma cells to RA190. We conclude that Rpn13 is not the physiologically relevant target of RA190.

摘要

Rpn13 是 26S 蛋白酶体中几种泛素受体之一。Rpn13 的 Cys88 被提议为 RA190 的主要靶标,RA190 是一种具有有趣抗癌活性的亲电小分子。在这里,我们研究了 RA190 通过与 Rpn13 结合来介导其细胞毒性作用的说法。我们没有发现事实如此的证据。在体外,RA190 对 Rpn13 的任何已知相互作用都没有可衡量的影响。在细胞内,我们没有看到 RA190 与 Rpn13 的任何其他残基在 C88 上发生物理结合。然而,在两种不同的细胞系中的化学蛋白质组学实验表明,数十种其他蛋白质与 RA190 大量结合。最后,增加或减少 HeLa 和黑色素瘤细胞中 Rpn13 的水平对 HeLa 或黑色素瘤细胞对 RA190 的敏感性没有影响。我们得出结论,Rpn13 不是 RA190 的生理相关靶标。

相似文献

1
Physical and Functional Analysis of the Putative Rpn13 Inhibitor RA190.RA190 假定的 Rpn13 抑制剂的物理和功能分析。
Cell Chem Biol. 2020 Nov 19;27(11):1371-1382.e6. doi: 10.1016/j.chembiol.2020.08.007. Epub 2020 Aug 27.
2
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.ADRM1 在卵巢高级别浆液性癌中早期且持续高表达。
J Ovarian Res. 2017 Aug 7;10(1):53. doi: 10.1186/s13048-017-0347-y.
3
Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling.双亚苄基哌啶酮 RA190 通过结合 RPN13 和抑制 NF-κB 信号通路治疗肝细胞癌。
BMC Cancer. 2020 May 6;20(1):386. doi: 10.1186/s12885-020-06896-0.
4
Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma.靶向多发性骨髓瘤中的蛋白酶体泛素受体Rpn13
Leukemia. 2016 Sep;30(9):1877-86. doi: 10.1038/leu.2016.97. Epub 2016 Apr 27.
5
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties.候选小分子 RPN13 抑制剂抗肿瘤特性的结构-功能分析。
PLoS One. 2020 Jan 15;15(1):e0227727. doi: 10.1371/journal.pone.0227727. eCollection 2020.
6
RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.RPN13/ADRM1抑制剂可逆转髓源性抑制细胞介导的免疫抑制作用。
Oncotarget. 2016 Oct 18;7(42):68489-68502. doi: 10.18632/oncotarget.12095.
7
Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets.Rpn13-Rpn2 复合物的结构为 Rpn13 和 Uch37 作为抗癌靶点提供了线索。
Nat Commun. 2017 Jun 9;8:15540. doi: 10.1038/ncomms15540.
8
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.手性和不对称性增加候选 ADRM1/RPN13 抑制剂的效力。
PLoS One. 2021 Sep 10;16(9):e0256937. doi: 10.1371/journal.pone.0256937. eCollection 2021.
9
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.开发并临床前验证了一种新型的骨髓瘤共价泛素受体 Rpn13 降解剂。
Leukemia. 2019 Nov;33(11):2685-2694. doi: 10.1038/s41375-019-0467-z. Epub 2019 Apr 8.
10
Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.蛋白质组学分析确定了通过靶向泛素受体 Rpn13 克服硼替佐米耐药的机制。
Leukemia. 2021 Feb;35(2):550-561. doi: 10.1038/s41375-020-0865-2. Epub 2020 May 18.

引用本文的文献

1
Optimization of the PROTAC linker region of the proteasome substrate receptor hRpn13 rationalized by structural modeling with molecular dynamics.通过分子动力学结构建模对蛋白酶体底物受体hRpn13的PROTAC接头区域进行优化
J Biol Chem. 2025 Apr 19;301(6):108520. doi: 10.1016/j.jbc.2025.108520.
2
Chemical tools to define and manipulate interferon-inducible Ubl protease USP18.用于定义和操纵干扰素诱导型泛素样蛋白酶USP18的化学工具。
Nat Commun. 2025 Jan 22;16(1):957. doi: 10.1038/s41467-025-56336-5.
3
Functional Characterization of Pathway Inhibitors for the Ubiquitin-Proteasome System (UPS) as Tool Compounds for CRBN and VHL-Mediated Targeted Protein Degradation.

本文引用的文献

1
Mechanistic Studies of the Multiple Myeloma and Melanoma Cell-Selective Toxicity of the Rpn13-Binding Peptoid KDT-11.Rpn13 结合肽拟肽 KDT-11 对多发性骨髓瘤和黑色素瘤细胞选择性毒性的机制研究。
Cell Chem Biol. 2020 Nov 19;27(11):1383-1395.e5. doi: 10.1016/j.chembiol.2020.08.008. Epub 2020 Aug 27.
2
Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling.双亚苄基哌啶酮 RA190 通过结合 RPN13 和抑制 NF-κB 信号通路治疗肝细胞癌。
BMC Cancer. 2020 May 6;20(1):386. doi: 10.1186/s12885-020-06896-0.
3
Re-Evaluating the Mechanism of Action of α,β-Unsaturated Carbonyl DUB Inhibitors b-AP15 and VLX1570: A Paradigmatic Example of Unspecific Protein Cross-linking with Michael Acceptor Motif-Containing Drugs.
泛素-蛋白酶体系统(UPS)通路抑制剂作为CRBN和VHL介导的靶向蛋白降解工具化合物的功能表征
ACS Chem Biol. 2025 Jan 17;20(1):94-104. doi: 10.1021/acschembio.4c00450. Epub 2025 Jan 3.
4
Delineating cysteine-reactive compound modulation of cellular proteostasis processes.描绘细胞蛋白质稳态过程中半胱氨酸反应性化合物的调节作用。
Nat Chem Biol. 2025 May;21(5):693-705. doi: 10.1038/s41589-024-01760-9. Epub 2024 Oct 24.
5
Integrative chemoproteomics reveals anticancer mechanisms of silver(i) targeting the proteasome regulatory complex.整合化学蛋白质组学揭示了银(I)靶向蛋白酶体调节复合物的抗癌机制。
Chem Sci. 2024 Feb 28;15(14):5349-5359. doi: 10.1039/d3sc04834a. eCollection 2024 Apr 3.
6
Pervasive aggregation and depletion of host and viral proteins in response to cysteine-reactive electrophilic compounds.宿主和病毒蛋白对半胱氨酸反应性亲电化合物的广泛聚集和耗竭。
bioRxiv. 2023 Nov 16:2023.10.30.564067. doi: 10.1101/2023.10.30.564067.
7
The prognostic value of 19S ATPase proteasome subunits in acute myeloid leukemia and other forms of cancer.19S ATP酶蛋白酶体亚基在急性髓系白血病及其他癌症中的预后价值
Front Med (Lausanne). 2023 Jul 12;10:1209425. doi: 10.3389/fmed.2023.1209425. eCollection 2023.
8
Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor.Up284 的开发及抗癌特性:一种新型的候选 ADAM13/RPN13 抑制剂。
PLoS One. 2023 Jun 14;18(6):e0285221. doi: 10.1371/journal.pone.0285221. eCollection 2023.
9
19S Proteasome Subunits as Oncogenes and Prognostic Biomarkers in FLT3-Mutated Acute Myeloid Leukemia (AML).19S 蛋白酶体亚基作为 FLT3 突变型急性髓系白血病(AML)中的癌基因和预后生物标志物。
Int J Mol Sci. 2022 Nov 23;23(23):14586. doi: 10.3390/ijms232314586.
10
Proteasome substrate receptors and their therapeutic potential.蛋白酶体底物受体及其治疗潜力。
Trends Biochem Sci. 2022 Nov;47(11):950-964. doi: 10.1016/j.tibs.2022.06.006. Epub 2022 Jul 9.
重新评估 α,β-不饱和羰基 DUB 抑制剂 b-AP15 和 VLX1570 的作用机制:含迈克尔受体结构的非特异性蛋白交联药物的典范范例。
J Med Chem. 2020 Apr 9;63(7):3756-3762. doi: 10.1021/acs.jmedchem.0c00144. Epub 2020 Mar 19.
4
A fluorescence polarization-based competition assay for measuring interactions between unlabeled ubiquitin chains and UCH37•RPN13.一种基于荧光偏振的竞争分析方法,用于测量未标记的泛素链与UCH37•RPN13之间的相互作用。
Anal Biochem. 2018 Jun 1;550:84-89. doi: 10.1016/j.ab.2018.04.018. Epub 2018 Apr 23.
5
Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets.Rpn13-Rpn2 复合物的结构为 Rpn13 和 Uch37 作为抗癌靶点提供了线索。
Nat Commun. 2017 Jun 9;8:15540. doi: 10.1038/ncomms15540.
6
Structure and energetics of pairwise interactions between proteasome subunits RPN2, RPN13, and ubiquitin clarify a substrate recruitment mechanism.蛋白酶体亚基RPN2、RPN13与泛素之间的成对相互作用的结构与能量学阐明了底物招募机制。
J Biol Chem. 2017 Jun 9;292(23):9493-9504. doi: 10.1074/jbc.M117.785287. Epub 2017 Apr 25.
7
Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.卡匹齐明是蛋白酶体异肽酶Rpn11的一种强效且特异性抑制剂。
Nat Chem Biol. 2017 May;13(5):486-493. doi: 10.1038/nchembio.2326. Epub 2017 Feb 28.
8
Discovery of an Inhibitor of the Proteasome Subunit Rpn11.蛋白酶体亚基Rpn11抑制剂的发现
J Med Chem. 2017 Feb 23;60(4):1343-1361. doi: 10.1021/acs.jmedchem.6b01379. Epub 2017 Feb 13.
9
Proteome-wide covalent ligand discovery in native biological systems.天然生物系统中全蛋白质组共价配体的发现
Nature. 2016 Jun 23;534(7608):570-4. doi: 10.1038/nature18002. Epub 2016 Jun 15.
10
Inhibition of Proteasome Activity Induces Formation of Alternative Proteasome Complexes.蛋白酶体活性的抑制诱导替代蛋白酶体复合物的形成。
J Biol Chem. 2016 Jun 17;291(25):13147-59. doi: 10.1074/jbc.M116.717652. Epub 2016 Apr 18.